CNGA3 and achromatopsia: CNGA3- and CNGB3-associated ACHM are in the focus, as several AAV-based gene supplementation therapy trials are ongoing (NCT02610582, NCT03758404, NCT02935517, NCT02599922), and one trial has already been successfully finished and published [20].